The cost of funding a clinical trial today can run biopharma companies upwards of $100mn, and that does not even begin to consider the costs of marketing and distribution necessary for a new life enhancing therapy to reach patients’ hands.
Global pharma businesses that spent the last decade building a robust pipeline of early stage compounds and indications are now faced with a wide portfolio of potential assets without the resources to fund their development.
The result? Drug makers who’ve made the investments necessary to ensure a strong R&D pipelines are now losing billions each year in potential revenue as promising new therapies are sitting dormant, waiting for their patent to expire. In this article, Ben van der Schaaf at Arthur D. Little discusses new funding models to progress low-priority clinical trials.